Qulipta, Latest FDA-Approved Preventive Treatment For Migraine, Enters A Highly Competitive Market On September 28th, the FDA approved a once-daily oral medicine, Qulipta (atogepant), for preventive treatment of episodic migraine in adults. It is the second FDA-approved, oral anti-CGRP drug for preventing migraine. The first was Nurtec ODT (rimegepant).